Polatuzumab vedotin plus rituximab with chemotherapy in newly diagnosed pediatric stage IV Burkitt lymphoma: case report highlighting early complete remission
Although pediatric Burkitt lymphoma is considered curable, some patients still have a poor prognosis. Lack of early or complete response is an adverse prognostic factor. Therefore, improving patients’ sensitivity to initial treatment and achieving comp…